Epigenetics-based therapeutics for myocardial fibrosis

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Epigenetics

Background:

• Myocardial fibrosis (MF) involves fibroblast proliferation and excessive extracellular matrix (ECM) deposition, leading to cardiac dysfunction and heart failure.
• The precise molecular mechanisms driving MF remain incompletely understood.
• Epigenetic modifications are increasingly recognized as key regulators of pro-fibrotic gene transcription in MF.

Purpose of the Study:

• To review current research on the epigenetic mechanisms underlying myocardial fibrosis.
• To discuss the role of DNA methylation, histone modification, noncoding RNAs, and m6A modification in MF.
• To explore potential therapeutic strategies targeting epigenetic regulators for MF.

Main Methods:

• Literature review of studies investigating epigenetic mechanisms in myocardial fibrosis.
• Analysis of research on DNA methylation, histone modifications, noncoding RNAs, and m6A in MF.
• Synthesis of findings on the interplay between different epigenetic mechanisms.

Main Results:

• Epigenetic processes, including DNA methylation, histone modification, and noncoding RNAs, significantly influence pro-fibrotic gene expression in MF.
• Emerging evidence highlights the role of m6A modification and crosstalk between epigenetic pathways in MF pathogenesis.
• Several molecular targets within epigenetic pathways show promise for therapeutic intervention.

Conclusions:

• Epigenetics plays a critical role in the development and progression of myocardial fibrosis.
• Understanding these epigenetic mechanisms provides novel insights into MF.
• Targeting epigenetic regulators presents a promising avenue for developing new treatments for heart failure caused by MF.